Insider Transactions at United Therapeutics Corporation (NASDAQ:UTHR)

Core Insights - United Therapeutics Corporation is a biotechnology company focused on developing products for chronic and life-threatening conditions, particularly in pulmonary arterial hypertension [1] Insider Transactions - Martine A. Rothblatt, Chairperson and CEO, sold 516 shares at approximately $534.99 each, leaving her with 8,414 shares [2][6] - Ray Kurzweil, Director, sold 4,910 shares at an average price of $489.02, reducing his holdings by 27.93% to 12,670 shares, valued at around $6.2 million [2][3][6] - Paul Mahon, Executive Vice President, sold 8,300 shares at an average price of $483.16, totaling over $4 million, marking an 18.39% reduction in his holdings, leaving him with 36,844 shares valued at approximately $17.8 million [3][6] Stock Performance - United Therapeutics' stock opened at $478.16, reflecting a 1.4% decrease, with a 50-day simple moving average of $482.51 and a 200-day simple moving average of $452.28 [4] - The company has a market capitalization of approximately $21 billion, a price-to-earnings ratio of 17.14, and a price-to-earnings-growth ratio of 1.75 [4] - The stock has experienced a 12-month low of $266.98 and a high of $537.19, with a price-to-sales ratio of about 7.38 and an enterprise value to sales ratio of around 6.89 [5] Financial Health - United Therapeutics has a strong current ratio of 6.60, indicating its ability to cover short-term liabilities with short-term assets [5] - The earnings yield is approximately 5.62%, reflecting the earnings generated from each dollar invested in the stock [5]